Frédéric London, Alice De Haan, Zohra Benyahia, Gaëtane Landenne, Thierry Duprez, Vincent van Pesch, Souraya El Sankari
{"title":"Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study.","authors":"Frédéric London, Alice De Haan, Zohra Benyahia, Gaëtane Landenne, Thierry Duprez, Vincent van Pesch, Souraya El Sankari","doi":"10.1007/s13760-025-02754-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment (CI) frequently occurs in relapsing-remitting multiple sclerosis (RRMS) and is assumed to be irreversible. Recent longitudinal studies highlighted the heterogeneity of CI in RRMS, challenging the traditional view of inevitable progression. Longitudinal studies exploring the baseline determinants of future cognitive decline are limited, and none yet explored the predictive value of patient-reported outcome measures (PROMs).</p><p><strong>Objective: </strong>To explore the evolutionary patterns of cognitive status in a cohort of RRMS patients initiating a new disease modifying treatment, and to determine whether PROMs may have a predictive value for future cognitive decline.</p><p><strong>Methods: </strong>This prospective study is a 36-month follow-up of 59 RRMS patients who underwent yearly a comprehensive, multiparametric assessment combining clinical, neuropsychological, MRI-derived metrics and a set of self-reported questionnaires. Lesion load and brain volumes were analyzed and processed by the automated MSmetrix<sup>®</sup> software (Icometrix<sup>®</sup>, Leuven, Belgium). A longitudinal logistic regression analysis was performed to investigate baseline predictors of future cognitive decline.</p><p><strong>Results: </strong>A total of 33 (56%) and 17 (35%) patients were defined as cognitively impaired at baseline and at the end of the study, respectively. Of these 33 patients, 20 showed either improvement and/or impairment in fewer cognitive domains at 36-month follow-up. Baseline physical disability as measured by EDSS was the best predictor for future cognitive decline (OR: 2.17; p = 0.03, 95% confidence interval = 1.07-4.38). None of the PROMs variables contributed to predict further cognitive decline.</p><p><strong>Conclusions: </strong>Our findings highlight the importance of considering the evolution of CI in MS as a dynamic phenomenon with a substantial heterogeneity.</p>","PeriodicalId":7042,"journal":{"name":"Acta neurologica Belgica","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13760-025-02754-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cognitive impairment (CI) frequently occurs in relapsing-remitting multiple sclerosis (RRMS) and is assumed to be irreversible. Recent longitudinal studies highlighted the heterogeneity of CI in RRMS, challenging the traditional view of inevitable progression. Longitudinal studies exploring the baseline determinants of future cognitive decline are limited, and none yet explored the predictive value of patient-reported outcome measures (PROMs).
Objective: To explore the evolutionary patterns of cognitive status in a cohort of RRMS patients initiating a new disease modifying treatment, and to determine whether PROMs may have a predictive value for future cognitive decline.
Methods: This prospective study is a 36-month follow-up of 59 RRMS patients who underwent yearly a comprehensive, multiparametric assessment combining clinical, neuropsychological, MRI-derived metrics and a set of self-reported questionnaires. Lesion load and brain volumes were analyzed and processed by the automated MSmetrix® software (Icometrix®, Leuven, Belgium). A longitudinal logistic regression analysis was performed to investigate baseline predictors of future cognitive decline.
Results: A total of 33 (56%) and 17 (35%) patients were defined as cognitively impaired at baseline and at the end of the study, respectively. Of these 33 patients, 20 showed either improvement and/or impairment in fewer cognitive domains at 36-month follow-up. Baseline physical disability as measured by EDSS was the best predictor for future cognitive decline (OR: 2.17; p = 0.03, 95% confidence interval = 1.07-4.38). None of the PROMs variables contributed to predict further cognitive decline.
Conclusions: Our findings highlight the importance of considering the evolution of CI in MS as a dynamic phenomenon with a substantial heterogeneity.
期刊介绍:
Peer-reviewed and published quarterly, Acta Neurologica Belgicapresents original articles in the clinical and basic neurosciences, and also reports the proceedings and the abstracts of the scientific meetings of the different partner societies. The contents include commentaries, editorials, review articles, case reports, neuro-images of interest, book reviews and letters to the editor.
Acta Neurologica Belgica is the official journal of the following national societies:
Belgian Neurological Society
Belgian Society for Neuroscience
Belgian Society of Clinical Neurophysiology
Belgian Pediatric Neurology Society
Belgian Study Group of Multiple Sclerosis
Belgian Stroke Council
Belgian Headache Society
Belgian Study Group of Neuropathology